Navigation Links
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Date:4/21/2009

tist and lead author of the study. "In data presented at this conference last year, we demonstrated that our fully human antibody PGN635 localizes to tumors and causes an increase in several inflammatory cytokines while decreasing an important anti-inflammatory cytokine. The new data we present confirms that PGN635 also triggers immune cells to produce other chemokines and cytokines that have the potential to alter the suppressed immune environment commonly found in tumors, attracting additional immune cells and stimulating more aggressive anti-tumor responses. We believe this upregulation of the immune response contributes to the encouraging anti-tumor effects demonstrated by PGN635 and other anti-PS antibodies."

A second study(2) presented on Monday by researchers from UT Southwestern Medical Center and Affitech demonstrated the ability of Peregrine's fully human PS-targeting antibody PGN632 to promote the maturation of dendritic cells, important antigen-presenting cells of the immune system. In the in vitro studies, immature dendritic cells cultured in the presence of PGN632 exhibited a significant increase in the production of inflammatory cytokines and chemokines. PGN632 also induced an increase in the expression of cell-surface molecules that are indicative of mature dendritic cells and that assist in antigen presentation functions, as well as in stimulating T-cell proliferation.

Dr. Xianming Huang, assistant professor of pharmacology at UT Southwestern Medical Center and lead author of the study, noted, "Dendritic cells are the professional antigen-presenting cells of the immune system and they play a crucial role in initiating adaptive immune responses. Dendritic cells must be mature, or activated, to be effective, yet tumors and other pathogens such as viruses often possess the ability to undermine this maturation, thereby suppressing the immune response. The results presented today suggest that by blocking e
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
2. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
3. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
4. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
5. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
6. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
9. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
10. Oridion Announces Significant Medical Studies Presented at STA
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN ) and Sanofi (EURONEXT: SAN and ... new Phase 3 ODYSSEY trials of alirocumab in people ... greater percent reduction from baseline in low-density lipoprotein cholesterol ... comparator.  Alirocumab is an investigational monoclonal antibody targeting PCSK9 ...
(Date:7/30/2014)... 30, 2014  Packaging Coordinators, Inc. (PCI) is pleased ... acquire Penn Pharmaceutical Services Limited (Penn Pharma). Penn Pharma is ... the United Kingdom and operates ... and Tokyo , Japan. Penn Pharma ... and Commercial dosage form manufacturing, as well as Clinical ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25
... Thirteen Abstracts Will Be Featured at Annual Kidney Care ... leading provider of kidney care services for those diagnosed ... with DaVita Clinical Research(R), today announced that company representatives ... 2009 Spring Clinical Meetings scheduled for March 25-29, 2009 ...
... Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... it has been selected to present the ... to Assess the Safety,Pharmacokinetics (PK) and Pharmacodynamics ... Type 2 Diabetes (T2DM)" at the upcoming ...
Cached Medicine Technology:DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 2DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 3DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 4DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium 5Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA) 2
(Date:7/30/2014)... 30, 2014 It is said that necessity ... to be true as a product sponsor for Lash ... Vegas this past June. , Lash Affair believes ... success of the eyelash industry through collaboration so Jenelle Paris, ... have supported NEESA ’s event. Lash Affair’s mission dovetails ...
(Date:7/30/2014)... July 30, 2014 Recently, Agebc.com, one ... industry, has released its new line of affordable ... girl dresses come in several popular styles: sequined ball-gown, ... designs in the company’s fresh assortment are: short chiffon ... by embroideries and of course the classic beautiful colored ...
(Date:7/30/2014)... study of high school students by University of Adelaide ... between insomnia-related mental health conditions among teens. , ... more than 300 Australian high school students aged 12-18 ... and the time of day they were most active ... in the journal Sleep Medicine , ...
(Date:7/30/2014)... could be created to diagnose diseases such as Alzheimer,s ... earlier intervention, according to new findings from the University ... components of memory using a combination of tests and ... create a diagnostic tool for distinguishing between different types ... amnesia caused by head trauma. , Dr Louis ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 4DSP’s new ... factor embedded system designed to provide a complete and ... communication. The system is housed in an enclosure measuring ... Kg. It features a low-power x86 CPU tightly coupled ... Mezzanine Card (FMC – VITA 57.1). The ...
Breaking Medicine News(10 mins):Health News:Lash Affair Launches a New Product as Sponsor of the First U.S. Lash Extension Competition 2Health News:Affordable Flower Girl Dresses Recently Unveiled at Agebc.com 2Health News:Teen insomnia is linked with depression and anxiety 2Health News:Hope for more accurate diagnosis of memory problems 2Health News:4DSP Introduces a Compact Platform for UAVs with Embedded Processing and Flexible IO 2Health News:4DSP Introduces a Compact Platform for UAVs with Embedded Processing and Flexible IO 3Health News:4DSP Introduces a Compact Platform for UAVs with Embedded Processing and Flexible IO 4
... Clinic have been able to find out subtle changes in ... of heart function by using the ultrasounds. They report that ... onset o heart damages like the heart attacks.// ,The ... optimal adjustment of cardiac pacemakers or perhaps better design of ...
... , it can be marketed as functional food ingredients, or ... they have been able to identify the molecular structure ... library of different flavonols. They also say that they are ... also compounds tailored to specific needs. , ,Several studies ...
... from tension-headaches, acupuncture may be the right treatment for ... that acupuncture can reduce the incidence of these headaches ... standard of clinical trials - researchers in Germany divided ... into three groups. ,Over an eight week ...
... and Lviv Regional Oncology center//, Ukraine has developed a ... of breast and ovarian cancer. ,However, they did ... to find a single reliable early protein, or 'marker', ... very successful," says LICR's Serhiy Souchelnytskyi, senior author of ...
... neurodegenerative and ultimately fatal disease// that slowly destroys the ... the ability to take care of themselves and require ... ,Based on findings of a recent study researchers say ... help slow the progression of Alzheimer's disease by reducing ...
... more than 21,100 consumers in 38 markets it was seen that ... fat content, while two in five people regularly check for calorie ... they understood food labeling, when they would check nutritional information and ... shopping. ,It was seen that in spite of all ...
Cached Medicine News:Health News:Ultrasounds To Detect Changes In Heart Motions 2Health News:Acupuncture May Be An Effective Treatment Against Tension-Headaches 2Health News:Molecular markers for early diagnosis of breast and ovarian cancer 2
69" 5 shelves electric rotating display with gunmetal grey frame. Lead time 6-8 weeks....
... impact for the marketing of optical frames ... frames allows your retail area to maximize ... eye-catching displays. The products are shown at ... Removable holders. Variable number of frames displayed ...
A quarter-vision dispensing case or table with a 6" high glass display area and halogen lights. Based on size of case, enjoy either 4, 5.5, 7 or 8 square feet respectively of elegant shelf space for ...
Eye-Kraft is an independent, full-service ophthalmic laboratory. It offers first-quality products, same-day service and overnight delivery with ongoing research and development....
Medicine Products: